<DOC>
	<DOCNO>NCT00000992</DOCNO>
	<brief_summary>To test effectiveness itraconazole prevent recurrence disseminate histoplasmosis AIDS patient . Histoplasmosis serious opportunistic infection patient AIDS . Amphotericin B use treat infection . Although response treatment generally good , 90 percent AIDS patient take amphotericin B treat histoplasmosis infection relapse ( , get disease ) within 12 month follow treatment . Ketoconazole use prevent relapse , available information suggest 50 percent AIDS patient relapse even ketoconazole treatment . A effective therapy prevent recurrence need . Itraconazole use successfully treat disseminated histoplasmosis non-AIDS patient hop may effective prevent histoplasmosis relapse .</brief_summary>
	<brief_title>A Study Itraconazole Preventing Return Histoplasmosis , Fungal Infection , Patients With AIDS</brief_title>
	<detailed_description>Histoplasmosis serious opportunistic infection patient AIDS . Amphotericin B use treat infection . Although response treatment generally good , 90 percent AIDS patient take amphotericin B treat histoplasmosis infection relapse ( , get disease ) within 12 month follow treatment . Ketoconazole use prevent relapse , available information suggest 50 percent AIDS patient relapse even ketoconazole treatment . A effective therapy prevent recurrence need . Itraconazole use successfully treat disseminated histoplasmosis non-AIDS patient hop may effective prevent histoplasmosis relapse . AIDS patient successfully treat amphotericin B acute first episode disseminate histoplasmosis select treatment . They receive daily oral dos itraconazole total 52 week . Patients experience significant toxicity relate drug may continue receive itraconazole last patient complete 52 week itraconazole therapy study drug discontinue prior complete 52 week therapy . AMENDED : Patients treat minimum 52 week . Patients complete 52 week remain study drug continue follow . If itraconazole becomes license histoplasmosis , study drug must discontinue end 52 week therapy time licensure patient receive 52 week therapy .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Histoplasmosis</mesh_term>
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Itraconazole therapy must begin 6 week discontinue primary amphotericin B therapy ; itraconazole therapy may begin immediately stop primary therapy amphotericin B . Allowed : Oral contraceptive . Methadone . Narcotics . Acyclovir . Acetaminophen . Sulfonamides . Trimethoprim / sulfamethoxazole . Aerosolized pentamidine Pneumocystis carinii pneumonia ( PCP ) PCP prophylaxis ( patient total CD4+ count &lt; 200 history PCP receive PCP prophylaxis ) . Treatment IND drug . Zidovudine . Topical antifungal . Discouraged : Antacids . Sucralfate . H2 blocker . Concurrent Treatment : Allowed : Radiation therapy mucocutaneous Kaposi 's sarcoma . Prior Medication : Required : Prior treatment amphotericin B disseminate histoplasmosis : minimum total dose 15 mg/kg patient &lt; 67 kg , 1 g patient &gt; 67 kg ; must administer 6 month less . Allowed : Amphotericin B maintenance therapy maximum 6 week follow completion primary therapy . Zidovudine . Prophylaxis Pneumocystis carinii pneumonia . Exclusion Criteria Coexisting Condition : Patients follow condition exclude : History allergy , intolerance , imidazoles azoles . Clinical finding active histoplasmosis . Histoplasmosis central nervous system . Inability take oral medication reliably severe malabsorption syndrome . Malignancies require cytotoxic therapy . Cultureproven systemic Mycobacterium tuberculosis , Mycobacterium aviumintracellulare , coccidioidomycosis , cryptococcosis . Concurrent Medication : Excluded : Amphotericin B maintenance therapy . Immunostimulants . Ketoconazole . Systemic antifungal . Steroids excess physiologic replacement dos . Cytotoxic chemotherapy . Investigational agent specifically allow . Antacids 4 hour 4 hour itraconazole . Concurrent Treatment : Excluded : Lymphocyte replacement . Patients follow condition exclude : History allergy , intolerance , imidazoles azoles . Clinical finding active histoplasmosis . Histoplasmosis central nervous system . Inability take oral medication reliably severe malabsorption syndrome . Malignancies require cytotoxic therapy . Cultureproven systemic Mycobacterium tuberculosis , Mycobacterium aviumintracellulare , coccidioidomycosis , cryptococcosis . Prior Medication : Excluded within 30 day study entry : Immunostimulants . Ketoconazole . Systemic antifungal . Steroids excess physiologic replacement dos . Cytotoxic chemotherapy . Prior Treatment : Excluded : Lymphocyte replacement . Risk Behavior : Excluded : Patients opinion investigator would undependable regard adherence protocol . Inclusion criterion : HIV infection document presence antibody , ELISA Western blot confirmation , serum p24 antigen , recovery HIV culture . Acute first episode disseminate histoplasmosis document recovery identification H. capsulatum culture obtain extrapulmonary site . Oriented person , place , time , able give write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Ketoconazole</keyword>
	<keyword>Histoplasmosis</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Antifungal Agents</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
</DOC>